Blood tests for tumor DNA to track colorectal cancer after treatment
Tests blood for leftover tumor DNA in adults with colorectal cancer.
Plain-language title generated from the registry record
Registry title: MRD Monitoring in Colorectal Cancer Using ctDNA
Key facts
- Where
- Brno, CzechiaSee the site
Where in Czechia
- Masaryk Memorial Cancer InstituteBrno, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Masaryk Memorial Cancer Institute
- Trial code
- NCT07895459
- Record updated
- 28 October 2026
- Original description
This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy. The objective is to detect minimal residual disease (MRD) early and to predict disease relapse or progression in patients with colorectal cancer (stages II-IV). By monitoring specific KRAS gene mutations (G12 and G13) using the ddPCR method, the study aims to improve risk stratification and treatment response monitoring following primary therapy.Read full original descriptionShow less
Monitoring of Minimal Residual Disease (MRD) in Selected Patients With Colorectal Cancer (Stages II-IV) Using Analysis of Circulating Tumor DNA (ctDNA) by the ddPCR Method
This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy. The objective is to detect minimal residual disease (MRD) early and to predict disease relapse or progression in patients with colorectal cancer (stages II-IV). By monitoring specific KRAS gene mutations (G12 and G13) using the ddPCR method, the study aims to improve risk stratification and treatment response monitoring following primary therapy.
Inclusion: Histologically confirmed diagnosis of colorectal cancer (clinical stage II, III, or IV); Presence of KRAS gene mutation (specifically G12 or G13 mutations) confirmed in the primary tumor tissue; Age 18 years or older at the time of inclusion; Patient scheduled for standard primary surgical resection, local treatment, or adjuvant therapy as per institutional guidelines; Signed written informed consent to participate in the study.
Exclusion: Active second primary malignancy that could interfere with ctDNA interpretation; Absence of target KRAS mutations (G12/G13) in the primary tumor; Inability or unwillingness to comply with scheduled blood sampling and follow-up visits.